Health state utilities for metastatic breast cancer in Taiwan
| Autor: | Yu Ko, Shao Chin Chiang, Tzu Chun Chou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Health utility Drug-Related Side Effects and Adverse Reactions Visual analogue scale Nausea Cost-Benefit Analysis Health Status Taiwan Adverse drug reactions Breast Neoplasms Time-trade-off lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Breast cancer medicine Humans 030212 general & internal medicine Drug reaction Aged business.industry Patient Preference General Medicine Middle Aged medicine.disease Time trade-off lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Metastatic breast cancer Cross-Sectional Studies 030220 oncology & carcinogenesis Expert opinion Family medicine Quality of Life Surgery Original Article Female Health utility value Quality-Adjusted Life Years medicine.symptom business |
| Zdroj: | Breast, Vol 51, Iss, Pp 57-64 (2020) The Breast : official journal of the European Society of Mastology |
| ISSN: | 1532-3080 |
| Popis: | Background New developments in medications for metastatic breast cancer (MBC) can be of great benefit to patients, but unfortunately these medicines also increase expenditures. Cost-utility analyses (CUAs) are needed to allocate health resources properly, and health utility values are required to calculate quality-adjusted life years in those CUAs. Objective The aims of this study were to measure health utility values for several MBC-related health states and certain breast cancer treatment-related grade 3/4 adverse drug reactions (ADRs). In addition, we examined whether different methods and respondents’ characteristics would influence the utility values elicited. Methods A cross-sectional survey was conducted. The visual analogue scale (VAS) and time trade-off (TTO) methods were used to measure health utilities. Four MBC and nine ADR health states were selected for evaluation based on literature review and expert opinion. Information about respondents’ demographic and clinical characteristics were collected to examine the relationship between utilities and participant characteristics. Results A total of 102 patients participated in this study. The TTO-elicited values were higher than the VAS-derived scores except for two MBC-related health states. Among the MBC health states assessed, the TTO preference score ranged from 0.04 (palliative MBC) to 0.62 (responding MBC). For grade 3/4 ADRs, the mean TTO-derived utility values ranged from 0.35 (nausea/vomiting) to 0.79 (fatigue). The ranking of the preference scores derived from the VAS was similar to that of the TTO-elicited scores. Conclusion This study obtained health state utility values for MBC and grade 3/4 ADRs using both the TTO and the VAS, which provides useful data for future CUAs. Highlights • This study obtained health state utility values for metastatic breast cancer (MBC) and grade 3/4 adverse drug reactions (ADRs) using both the time trade-off (TTO) and the visual analogue scale (VAS), which provides useful data for future cost-utility analyses. • Among the MBC health states assessed, the TTO preference score ranged from 0.04 (palliative MBC) to 0.62 (responding MBC). • For grade 3/4 ADRs, the mean TTO-derived utility values ranged from 0.35 (nausea/vomiting) to 0.79 (fatigue). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect